DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?

TY - JOUR

T1 - DNA Methyltransferase Inhibitors in Myeloid Cancer

T2 - Clonal Eradication or Clonal Differentiation?

AU - Ørskov, Andreas Due

AU - Grønbæk, Kirsten

PY - 2017/9/1

Y1 - 2017/9/1

N2 - DNA methyltransferase inhibitors, so-called hypomethylating agents (HMAs), are the only drugs approved for the treatment of higher-risk myelodysplastic syndromes and are widely used in this context. However, it is still unclear why some patients respond to HMAs, whereas others do not. Recent sequencing efforts have identified molecular disease entities that may be specifically sensitive to these drugs, and many attempts are being made to clarify how HMAs affect the malignant clone during treatment. Here, we review the most recent data on the clinical effects of HMAs in myeloid malignancies.

AB - DNA methyltransferase inhibitors, so-called hypomethylating agents (HMAs), are the only drugs approved for the treatment of higher-risk myelodysplastic syndromes and are widely used in this context. However, it is still unclear why some patients respond to HMAs, whereas others do not. Recent sequencing efforts have identified molecular disease entities that may be specifically sensitive to these drugs, and many attempts are being made to clarify how HMAs affect the malignant clone during treatment. Here, we review the most recent data on the clinical effects of HMAs in myeloid malignancies.

U2 - 10.1097/PPO.0000000000000282

DO - 10.1097/PPO.0000000000000282

M3 - Review

C2 - 28926428

SN - 1528-9117

VL - 23

SP - 277

EP - 285

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

IS - 5

ER -